Cachexia and Life Expectancy: Understanding Wasting Syndrome Prognosis

Cachexia is a complex metabolic wasting syndrome characterized by involuntary weight loss (>5% in 6 months), muscle atrophy, fatigue, anorexia, and systemic inflammation. It occurs in advanced cancer, chronic kidney disease, heart failure, COPD, and other chronic illnesses.

Impact on Life Expectancy

Cachexia significantly shortens survival, but prognosis varies widely based on:

  • Underlying disease type and stage
  • Severity of weight loss and muscle depletion
  • Response to nutritional and pharmacologic interventions
  • Patient’s overall functional status

Median survival is often less than one year, yet some patients live longer with aggressive multimodal management.

Management Strategies

  • Nutritional support: High‑calorie, high‑protein oral supplements; enteral/parenteral nutrition if needed.
  • Pharmacotherapy: Appetite stimulants (megestrol, corticosteroids), anabolic agents (selective androgen receptor modulators), anti‑inflammatory drugs (NSAIDs, omega‑3 fatty acids).
  • Exercise: Resistance training to preserve muscle mass and function.
  • Palliative care: Early integration improves quality of life and may extend survival.

Key Points

Cachexia is not simple starvation; it is driven by tumor‑ or disease‑derived factors that alter metabolism. A multidisciplinary approach (oncology, nutrition, palliative care, physiotherapy) offers the best chance to mitigate its impact.

Anorexia - Related Articles